Clinical Trial Update: Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of selinexor in relapsed or refractory PTCL or CTCL; study terminated with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | Status: TERMINATED | Results posted: 2018-08-20